A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H.
Terui Y, et al. Among authors: kanemura n.
Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4.
Cancer Sci. 2021.
PMID: 33942442
Free PMC article.
Clinical Trial.